ProPhase Labs Announces Formation of ProPhase BioPharma, Inc. (PBIO) for the Licensing and Development of Novel Drugs, Compounds and Biotechnology
June 28, 2022 08:30 ET
|
ProPhase Labs, Inc.
Company Also Announces First Licensing Agreement for PBIO with Global BioLife, Inc. for broad based Anti-Viral Fighting Compounds Equivir and Equivir G Garden City, NY, June 28, 2022 (GLOBE...
Vallon Pharmaceuticals Reports Additional Pharmacokinetic and Pharmacodynamic Data from SEAL Study of ADAIR
May 12, 2022 08:30 ET
|
Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, May 12, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
Vallon Pharmaceuticals to Present at the Q3 Virtual Investor Summit
August 11, 2021 08:05 ET
|
Vallon Pharmaceuticals Inc.
Live video webcast with David Baker, President and CEO of Vallon, on Wednesday, August 18th 12:30 PM ET PHILADELPHIA, PA, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:...
Vallon Pharmaceuticals to Participate at the 4th Annual Neuroscience Innovation Forum
April 26, 2021 09:05 ET
|
Vallon Pharmaceuticals Inc.
David Baker, President and CEO of Vallon to participate in the virtual Advances in Neuropsychiatry Panel on April 29th at 10:30 AM ET PHILADELPHIA, PA, April 26, 2021 (GLOBE NEWSWIRE) -- Vallon...
Vallon Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference
March 03, 2021 08:35 ET
|
Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, March 03, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
Vallon Pharmaceuticals Announces Closing of Initial Public Offering
February 12, 2021 15:30 ET
|
Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON) (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
Vallon Pharmaceuticals Announces Pricing of Initial Public Offering
February 09, 2021 22:24 ET
|
Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that...
Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 39th Annual Global Healthcare Conference
June 06, 2018 16:02 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 06, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), today announced that it will present at the Goldman Sachs 39th Annual Global Healthcare Conference. ...
Momenta Pharmaceuticals Announces Presentation on M281, an Anti-FcRn Monoclonal Antibody, at 11th International Congress on Autoimmunity
May 17, 2018 16:05 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 17, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) today announced the upcoming presentation describing the broad potential for anti-FcRn therapeutics and...
Momenta Pharmaceuticals to Webcast Presentation at the Bank of America Merrill Lynch Health Care Conference 2018
May 10, 2018 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 10, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...